Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (monocyte progenitors) | 0.10 |
| chemistry Open Targets | compounds already reach it: nemolizumab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 6494
Sealed predictions
- IL31RA in dopamine neurons, braak-0.42 (p 0.258) → -0.22 (p 0.570)receipt 6502
Swarm cases
receipt 6502: IL31RA in dopamine neurons, braak
- power
- full sample -0.14 (p 0.567, n 18), 95% CI -0.57 to +0.35. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.35 (p 0.156, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.34 (p 0.167, n 18). could be the mix.
- skeptic
- leave-one-out range -0.23 to -0.04, sign flips 0; without severely affected donors -0.14 (p 0.567, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IL31RA in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts